GHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
GH Research PLC (GHRS) is not a strong buy at this time for a beginner, long-term investor. While there are positive catalysts such as hedge fund interest and an optimistic analyst rating, the company's financial performance remains weak, with no revenue and negative net income. Additionally, technical indicators are neutral, and there are no strong trading signals. Given the investor's preference for long-term growth and the lack of immediate strong entry signals, holding off for now is the prudent choice.
The MACD is below zero and negatively contracting, indicating a lack of upward momentum. RSI is neutral at 52.673, suggesting no clear overbought or oversold condition. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the price is near a key pivot point (15.583) with resistance at 16.347 and support at 14.819. Overall, the technical indicators are mixed to neutral.
Hedge funds are significantly increasing their positions in the stock, with a 735.47% increase in buying over the last quarter.
RBC Capital raised the price target to $40 from $33 and maintains an Outperform rating, citing optimism about GH001's long-term sales potential.
The company has no revenue and continues to post negative net income (-$14.02M in Q3 2025).
The stock experienced a pre-market drop of -3.17% and a regular market drop of -0.76%, reflecting weak short-term sentiment.
No recent news or congress trading data to provide additional support.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income of -$14.02M, which improved by 15.73% YoY but remains negative. EPS was -0.23, with no YoY growth. Gross margin remains at 0%. Overall, the financials indicate a lack of profitability and growth.
RBC Capital raised the price target to $40 from $33 and maintains an Outperform rating. Analysts are optimistic about the long-term sales potential of GH001, following discussions with management, payers, and doctors.
